Review



serca2a primary antibody cst4388  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc serca2a primary antibody cst4388
    Protein expression levels and representative images. ( a ) <t>SERCA2a</t> protein expression level normalized to GAPDH; ( b ) The ratio of p-PLN to PLN; ( c ) The ratio of PLN to SERCA2a. C, Control ( n = 5); D, Diabetic ( n = 5); SV, Sacubitril/valsartan-treated diabetic ( n = 5); and V, Valsartan-treated diabetic ( n = 4). *, p < 0.05; **, p < 0.01 compared to control.
    Serca2a Primary Antibody Cst4388, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/serca2a+primary+antibody+cst4388/pmc11476658-305-22-38?v=Cell+Signaling+Technology+Inc
    Average 90 stars, based on 1 article reviews
    serca2a primary antibody cst4388 - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "Sacubitril/Valsartan Combination Partially Improves Cardiac Systolic, but Not Diastolic, Function through β-AR Responsiveness in a Rat Model of Type 2 Diabetes"

    Article Title: Sacubitril/Valsartan Combination Partially Improves Cardiac Systolic, but Not Diastolic, Function through β-AR Responsiveness in a Rat Model of Type 2 Diabetes

    Journal: International Journal of Molecular Sciences

    doi: 10.3390/ijms251910617

    Protein expression levels and representative images. ( a ) SERCA2a protein expression level normalized to GAPDH; ( b ) The ratio of p-PLN to PLN; ( c ) The ratio of PLN to SERCA2a. C, Control ( n = 5); D, Diabetic ( n = 5); SV, Sacubitril/valsartan-treated diabetic ( n = 5); and V, Valsartan-treated diabetic ( n = 4). *, p < 0.05; **, p < 0.01 compared to control.
    Figure Legend Snippet: Protein expression levels and representative images. ( a ) SERCA2a protein expression level normalized to GAPDH; ( b ) The ratio of p-PLN to PLN; ( c ) The ratio of PLN to SERCA2a. C, Control ( n = 5); D, Diabetic ( n = 5); SV, Sacubitril/valsartan-treated diabetic ( n = 5); and V, Valsartan-treated diabetic ( n = 4). *, p < 0.05; **, p < 0.01 compared to control.

    Techniques Used: Expressing, Control



    Similar Products

    serca2a primary antibody cst4388  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc serca2a primary antibody cst4388
    Protein expression levels and representative images. ( a ) <t>SERCA2a</t> protein expression level normalized to GAPDH; ( b ) The ratio of p-PLN to PLN; ( c ) The ratio of PLN to SERCA2a. C, Control ( n = 5); D, Diabetic ( n = 5); SV, Sacubitril/valsartan-treated diabetic ( n = 5); and V, Valsartan-treated diabetic ( n = 4). *, p < 0.05; **, p < 0.01 compared to control.
    Serca2a Primary Antibody Cst4388, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/serca2a+primary+antibody+cst4388/pmc11476658-305-22-38?v=Cell+Signaling+Technology+Inc
    Average 90 stars, based on 1 article reviews
    serca2a primary antibody cst4388 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Protein expression levels and representative images. ( a ) SERCA2a protein expression level normalized to GAPDH; ( b ) The ratio of p-PLN to PLN; ( c ) The ratio of PLN to SERCA2a. C, Control ( n = 5); D, Diabetic ( n = 5); SV, Sacubitril/valsartan-treated diabetic ( n = 5); and V, Valsartan-treated diabetic ( n = 4). *, p < 0.05; **, p < 0.01 compared to control.

    Journal: International Journal of Molecular Sciences

    Article Title: Sacubitril/Valsartan Combination Partially Improves Cardiac Systolic, but Not Diastolic, Function through β-AR Responsiveness in a Rat Model of Type 2 Diabetes

    doi: 10.3390/ijms251910617

    Figure Lengend Snippet: Protein expression levels and representative images. ( a ) SERCA2a protein expression level normalized to GAPDH; ( b ) The ratio of p-PLN to PLN; ( c ) The ratio of PLN to SERCA2a. C, Control ( n = 5); D, Diabetic ( n = 5); SV, Sacubitril/valsartan-treated diabetic ( n = 5); and V, Valsartan-treated diabetic ( n = 4). *, p < 0.05; **, p < 0.01 compared to control.

    Article Snippet: GAPDH (14C10) primary antibody (CST2118S) (RRID: AB_561053), PLN primary antibody (CST8495) (RRID: AB_10949105), p-PLN (PLN ser16/thr17 ) primary antibody (CST8496) (RRID: AB_10949102), SERCA2a primary antibody (CST4388) (RRID: AB_2227684), and antirabbit secondary antibody (CST7074) (RRID: AB_2099233) were obtained from Cell Signaling (Danvers, Massachusetts, USA).

    Techniques: Expressing, Control